1Parkin DM, Bray F, Ferlay J, et al. Global cancer statistics, 2002 [J]. CA Cancer J Clin, 2005, 55 (2): 74-105.
2Muldrew KL, Beqaj SH, Hart J, et al. Evaluation of a Digene-recommended algorithm for human papillomavirus low-positive results present in a "retest zone"[J]. Am J Clin Pathol, 2007, 127( 1 ): 97-102.
3Schledermarm D, Ejersbo D, Hoelund B. Improvement of diagnostic accuracy and screening conditions with liquid-based cytology [J]. Diagn Cytopathol, 2006, 34( 11 ): 780-785.
4Lerma E, Quintana M J, Quilez M, et al. Effectiveness of liquidbased cytology and papanicolaou tests in a low risk population [J]. Acta Cytol, 2007, 51 (3): 399-406.
5Waits AE, Thomas P. Correlation of manual screening and automated (AutoPap 300) analysis of conventional cervicovaginai smears with HPV typing using Digene HC Ⅱ assay[J]. Diagn Cytopathol, 2003, 29(5): 256-261.
6Fremont-Smith M, Marino J, Griffin B, et al. Comparison of the SurePath liquid-based Papanicolaou smear with the conventional Papanicolaou smear in a muhisite direct-to-vial study [J]. Cancer, 2004, 102(5): 269-279.
7Mattosinho de Castro Ferraz Mda G, Nicolau SM, Stavale JN, et al. Cervical biopsy-based comparison of a new liquid .based thin-layer preparation with conventional Pap smears [J]. Diagn Cytopathol, 2004, 30 (4): 220-226.
8Llewellyn H. Relationship between the cytologic reporting rate for high-grade squamous intraepithelial lesion or worse and Papanicolaou smear sensitivity: a simple mathematic proof with practical implications[J]. Cancer, 2007, 25; 111(3): 137-40.
9Smith JS, Lindsay L, Hoots B, et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: A meta-analysis update[J]. Int J Cancer, 2007, 121 (3): 621-632.
10Monsonego J. Cervical cancer prevention: the impact of HPV vaccination[J]. Gynecol Obstet Fertil, 2006, 34(3): 189-201.
